Charles River Acquires ChanTest
News Oct 31, 2014
Headquartered in Cleveland, Ohio, ChanTest offers a panel of more than 120 validated assays to test ion channels, which we believe is the most comprehensive panel in the industry. ChanTest scientists are thought leaders in the field of ion channels and are currently working with the FDA on the Comprehensive in vitro Proarrhythmia Assay (CiPA) guidelines.
As researchers increasingly incorporate ion channel testing into their molecule design process, access to more comprehensive ion channel assay panels will be invaluable to supporting their drug discovery efforts. With this acquisition, we are emerging as the market-leading CRO in ion channel drug discovery and associated in vitro safety testing.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE